Gout flare prophylaxis during management of chronic gout with febuxostat, a non-purine selective inhibitor of xanthine oxidase.

被引：0
|
作者：
Wortmann, R
Becker, MA
Schumacher, HR
MacDonald, P
Palo, WA
Joseph-Ridge, N
机构：
[1] Univ Oklahoma, Tulsa, OK USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Univ Penn, VAMC, Philadelphia, PA 19104 USA
[4] TAP Pharmaceut Prod Inc, Lake Forest, IL USA
来源：
ARTHRITIS AND RHEUMATISM | 2004年 / 50卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S335 / S336
页数：2
相关论文
共 49 条
  • [1] Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout
    Schumacher, HR
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (07) : 893 - 903
  • [2] Febuxostat: A Novel Non-Purine Selective Inhibitor of Xanthine Oxidase for the Treatment of Hyperuricemia in Gout
    Yu, Kuang-Hui
    RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2007, 1 (01) : 69 - 75
  • [3] Magnetic resonance imaging of gouty tophi during treatment with febuxostat, a non-purine selective inhibitor of xanthine oxidase.
    Schumacher, HR
    Becker, MA
    Wortmann, R
    MacDonald, P
    Palo, WA
    Streit, J
    Lademacher, C
    Joseph-Ridge, N
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S336 - S336
  • [4] Long-term safety and efficacy of febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in subjects with hyperuricemia and gout
    Schumacher, HR
    Wortmann, R
    Becker, M
    MacDonald, P
    Palo, W
    Streit, J
    Lademacher, C
    Joseph-Ridge, N
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 498 - 498
  • [5] Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia
    Komoriya, K
    Hoshide, S
    Takeda, K
    Kobayashi, H
    Kubo, J
    Tsuchimoto, M
    Nakachi, T
    Yamanaka, H
    Kamatani, N
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2004, 23 (8-9): : 1119 - 1122
  • [6] Febuxostat: A selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout
    Bruce, Susan P.
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (12) : 2187 - 2194
  • [7] Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase
    Takano, Y
    Hase-Aoki, K
    Horiuchi, H
    Zhao, L
    Kasahara, Y
    Kondo, S
    Becker, MA
    LIFE SCIENCES, 2005, 76 (16) : 1835 - 1847
  • [8] Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase
    Grabowski, Brian
    Khosravan, Reza
    Wu, Jing-Tao
    Vernillet, Laurent
    Lademacher, Christopher
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (01) : 57 - 64
  • [9] Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in an allopurinol-controlled phase III clinical trial in Japanese subjects with gout or hyperuricemia.
    Kamatani, N
    Fujimori, S
    Hada, T
    Hosoya, T
    Matsuzawa, Y
    Ueda, T
    Yamanaka, H
    Kato, R
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S336 - S337
  • [10] Effect of renal impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat (TMX-67), a novel non-purine selective inhibitor of xanthine oxidase.
    Swan, S
    Khosravan, R
    Mayer, MD
    Wu, JT
    Pa, WA
    MacDonald, PA
    Vernillet, L
    Joseph-Ridge, N
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S529 - S529
12345